Global Thyroid Cancer Diagnostics Market Size To Exceed USD 5.36 Billion by 2033: Market Growth Report

Global Thyroid Cancer Diagnostics Market Size To Exceed USD 5.36 Billion by 2033

According to a research report published by Spherical Insights & Consulting, The Global Thyroid Cancer Diagnostics Market Size is Expected to Grow from USD 2.90 Billion in 2023 to USD 5.36 Billion by 2033, at a CAGR of 6.34% during the forecast period 2023-2033.  

Browse 210 market data Tables and 45 Figures spread through 190 Pages and in-depth TOC on the Global Thyroid Cancer Diagnostics Market Size, Share, and COVID-19 Impact Analysis, By Cancer Type (Papillary Carcinoma and Follicular Carcinoma), By Technique (Imaging, Biopsy, and Blood Test), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033

The global thyroid cancer diagnostics market refers to the industry involved in the creation, manufacturing, and distribution of instruments and technology for thyroid cancer detection. It includes molecular testing, biopsy techniques, and imaging systems. Further, growing awareness of early diagnosis, technological advancements, and an increase in thyroid cancer cases are contributing to the market expansion. Key driving factors for the growth of thyroid cancer patients include increasing healthcare improvements, encouraging government programs, and the increased global need for precise, effective, and non-invasive diagnostic procedures. However, limited qualified specialists, high diagnostic prices, restricted access in low-income areas, and potential inaccuracies in some diagnostic techniques could prevent the broad acceptance and market expansion.

The papillary carcinoma segment accounted for the largest revenue share in 2023 and is projected to grow at a significant CAGR during the forecast period.

On the basis of cancer type, the global thyroid cancer diagnostics market is divided into papillary carcinoma and follicular carcinoma. Among these, the papillary carcinoma segment accounted for the largest revenue share in 2023 and is projected to grow at a significant CAGR during the forecast period. The segment growth is attributed to increasing awareness of illnesses and the development of healthcare, encouraging programs, and continuing research focused on enhancing papillary thyroid cancer early detection and treatment.

The imaging segment accounted for the highest share in 2023 and is anticipated to grow at a significant CAGR during the forecast period.

On the basis of technique, the global thyroid cancer diagnostics market is divided into imaging, biopsy, and blood test. Among these, the imaging segment accounted for the highest share in 2023 and is anticipated to grow at a significant CAGR during the forecast period. The segment growth is driven by a growing AI integration, imaging technology developments, and their ability of imaging to be precise.

North America is anticipated to hold the largest share of the global thyroid cancer diagnostics market over the predicted timeframe.

North America is anticipated to hold the largest share of the global thyroid cancer diagnostics market over the predicted timeframe. The regional market growth is driven by a high incidence of thyroid cancer, a sophisticated healthcare system, widespread access to innovative diagnostic tools, strong molecular diagnostics adoption, advantageous reimbursement practices, government-led early detection programs, active research and development expenditures, and awareness campaigns.

Asia Pacific is expected to grow at the fastest CAGR in the global thyroid cancer diagnostics Market during the forecast period. The regional market growth can be attributed because of urbanization, more awareness, government-led screening programs, enhanced diagnostic infrastructure, rising cancer incidence, increased healthcare spending, and the emergence of large companies that provide molecular diagnostic and advanced imaging technologies.

Company Profiling

Major vendors in the global thyroid cancer diagnostics market are Abbott, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., Siemens Healthcare GmbH, Bio-Rad Laboratories, Inc, GE HealthCare, Hologic, Inc., Koninklijke Philips N.V., Toshiba Corporation, Agilent Technologies, Inc., Illumina, Inc., and Others.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development

• In April 2025, A groundbreaking AI model for thyroid cancer diagnosis developed by researchers from the University of Hong Kong (HKUMed), the InnoHK Laboratory of Data Discovery for Health, and collaboration with the London School of Hygiene & Tropical Medicine. This model achieves over 90% accuracy in classifying thyroid cancer stages and risk categories.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global thyroid cancer diagnostics market based on the below-mentioned segments: 

Global Thyroid Cancer Diagnostics Market, By Cancer Type

• Papillary Carcinoma
• Follicular Carcinoma

Global Thyroid Cancer Diagnostics Market, By Technique

• Imaging
• Biopsy
• Blood Test

Global Thyroid Cancer Diagnostics Market, Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Uk
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa